The Effects Of Human Urinary Kallikrein On Acute Cerebral Infarction Of Different Subtype

ObjectiveTo evaluate the efficacy and side-effects of human Urinary kallikrein in treatment of patients with acute cerebral infarction of different subtype.MethodsA total 126 in patients with acute cerebral infarction between 6h-7d of onset were allocated to one of four OCSP subtypes at the first assessment and randomly divided into treatment group (n=54) and control group (n=51). Control group and treatment group received Salvia miltiorrhiza and human urinary kallikrein for 10 days, respectively. The neurological deficits scale (NIHSS), Barthel Index, handicap level(mRS)and blood pressure were assessed during human urinary kallikrein intravenous infusion. And the mRS is followed by a follow-up at the end of the first month.Results1. At the end of treatment, the NIHSS,mRS scores both decreased and the ADL scores increased (P＜0.05)。2. NIHSS,mRS scores were lower than control group (P＜0.05), ADL scores and the effective rate were higher than control group (P＜0.05)。3. the effective rate in treatment of each subtype was higher than that in control group (P＜0.05)。4.mRS score of treatment group at the end of the first month was more significantly reduced than that at the end of treatment and mRS score of control group at the end of the first month (P＜0.01)。 5.one case of blood pressure drop were observed and considered to be caused by denying using of anti-hypertensive drug ACEIConclusionsHuman urinary kallikrein which is safe in clinical use could reduce neurological deficits and significantly improve prognosis in a wider time window. And it is an effective treatment against TACI,TACI,POCI patients of acute cerebral infarction who are beyond the time window of thrombolysis.